Business Wire - May 22, 2003

Calypte and Planned Parenthood Federation are working together to develop education and training materials, patient awareness materials and a customized testing service to facilitate increased and easier access to urine-based HIV testing.

Planned Parenthood Federation of America provides comprehensive reproductive and complementary health care services, advocates public policies that guarantee the rights and ensures access to such services, provides educational programs, and promotes research and the advancement of technology in reproductive health care. Planned Parenthood operates approximately 875 health centers in 49 states and Washington, D.C., and serves nearly five million men, women and teenagers every year.

"All individuals worldwide have the right to nondiscriminatory, confidential access to the full range of voluntary reproductive health care services that are proven safe and effective, which includes the prevention and treatment of sexually transmitted diseases," said Dr. Vanessa Cullins, Planned Parenthood's Vice-President for Medical Affairs.

"With HIV transmission through heterosexual sex rapidly growing for women and particularly younger women in their teens, urine testing offers a simple and non-invasive means of testing that is more acceptable to many people than having blood drawn. The ability to screen for HIV, pregnancy and sexually transmitted diseases from the same urine specimen is an added convenience for both our clients and our healthcare providers."

Nancy Katz, Calypte's President and CEO, stated, "We are very pleased to have the opportunity to work closely with Planned Parenthood Federation to address the spread of HIV/AIDS. This relationship presents Calypte with an excellent opportunity to further expand the awareness of and access to our urine-based HIV testing. Independent studies have indicated that more people will voluntarily be tested for HIV if urine is offered as an alternative to blood testing. Both Calypte and Planned Parenthood Federation share a common goal of increasing the number of people who are voluntarily tested and are aware of their HIV status."

About Planned Parenthood Federation of America:

Planned Parenthood Federation of America, headquartered in New York, N.Y., is the nation's largest and most trusted voluntary reproductive health care organization. Planned Parenthood Federation of America provides comprehensive reproductive and complementary health care services, advocates public policies that guarantee the rights and ensures access to such services, provides educational programs, and promotes research and the advancement of technology in reproductive health care. Planned Parenthood operates approximately 875 health centers in 49 states and Washington, D.C., and serves nearly five million men, women and teenagers every year. Additional information about the mission and services offered by Planned Parenthood Federation can be found at www.ppfa.org.

About Calypte Biomedical:

Calypte Biomedical Corporation, headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte's tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples. The company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically and painlessly. Calypte markets its products in countries worldwide through international distributors and strategic partners. Current product labeling, including specific product performance claims, can be found at www.calypte.com.

Statements in this press release that are not historical facts are forward-looking statements, including statements regarding announcements of financial results and presentations by the Company. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K for the year ended December 31, 2002, and its subsequent filings with the SEC.

CONTACT: Calypte Biomedical Corporation

Pamela South, 510/749-5100

email: psouth@calypte.com

or

Planned Parenthood Federation

PPFA Media Relations, 212/261-4650

or

Sitrick & Company (Investor Relations)

Joe Bunning, 310/788-2850

email: joe_bunning@Sitrick.com

SOURCE: Calypte Biomedical Corporation

030522
BW030505

Copyright © 2003 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .